Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer, Metastatic Cancer
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408772
- Testing
- bevacizumab, capecitabine, oxaliplatin
- Where
- United States
- Sponsor
- University of California, Davis
Colorectal Cancer
Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients
The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6…
- Trial name
- NCT00335595
- Testing
- XELOXA, XELOXA-A
- Where
- Spain
- Volunteers
- 480 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Unresectable Metastatic Colo-rectal Cancer
Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in combination with intravenous chemotherapy versus intravenous chemotherapy alone in the treatment of unresectable liver metastases in…
- Trial name
- PARAGON (NCT00816777)
- Testing
- Chemoembolization with irinotecan Bead, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Generic Devices Consulting, Inc.
Colorectal Cancer Metastatic
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only…
- Trial name
- SULTAN (NCT03164655)
- Testing
- Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- UNICANCER
Colorectal Cancer Stage IV, Circulating Tumor Cell
Treatment Response Prediction System of mCRC Patients Based on CTC
This study enrolling patients with metastatic colorectal cancer. Detecting CTC at different points in the treatment process. Descripting the molecular atlas of CTC in mCRC patients.
- Trial name
- NCT04917276
- Testing
- Circulating tumor cell
- Volunteers
- 100 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic
Local Consolidative Therapy in Colorectal Cancer
This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of…
- Trial name
- NCT05062720
- Testing
- Local consolidative therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
BRAF V600E-mutant Metastatic Colorectal Cancer
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in…
- Trial name
- BEACON CRC (NCT02928224)
- Testing
- Encorafenib, Binimetinib, Cetuximab
- Where
- 418 sites in United States, Argentina and 25 more
- Volunteers
- 702 people
- Sponsor
- Pfizer
Colorectal Neoplasms, Hepatocellular Carcinoma
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC.
- Conditions
- Colorectal Neoplasms, Hepatocellular Carcinoma, Neoplasm Metastasis
- Trial name
- NCT02882659
- Testing
- Dendritic Killer Cell (DKC)
- Volunteers
- 18 people
- Sponsor
- FullHope Biomedical Co., Ltd.
Metastatic Colorectal Cancer
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
This is a personalized anti-cancer vaccine protocol which includes an in-situ (in the body) cancer vaccine step which combines killing a single metastatic tumor lesion by use of cryoablation in order to cause the release of…
- Trial name
- NCT01741038
- Testing
- AlloStim®, cryoablation, Physician's Choice (PC)
- Where
- Thailand
- Sponsor
- Mirror Biologics, Inc.
Colorectal Cancer Metastatic
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
The aim on this study is to assess the safety and efficacy of the anti-VEGFR2 monoclonal antibody olinvacimab and the capecitabine in patients with metastatic colorectal carcinoma who failed two prior chemotherapies
- Trial name
- NCT04751955
- Testing
- Olinvacimab added to Capecitabine
- Sponsor
- Korean Cancer Study Group
Quality of Life
Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer
The purpose of this study is to determine whether medically tailored meals (HDTM) can improve quality of life for patients with metastatic cancer.
- Trial name
- NCT02887235
- Testing
- Home Delivered, Medically Tailored Meals (HDTM)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Metastatic Colorectal Cancer
mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy
A multicenter,open,prospective randomized controlled trial;11 study center in China; Plan to enroll 328 patients（ Power Analysis and Sample Size ）.Comparing FOLFIRI with mFOLFOX6,Superiority design.Investigate difference…
- Trial name
- NCT05362617
- Testing
- FOLFIRI
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Colorectal Cancer Metastatic
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC (metastatic colorectal cancer) confirmed in liquid biopsies before starting second line…
- Trial name
- BEYOND (NCT03751176)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 18 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer, Metastatic Cancer
Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899210
- Testing
- laboratory biomarker analysis, cryosurgery, radiofrequency ablation
- Volunteers
- 75 people
- Sponsor
- University Hospital, Grenoble
Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or…
- Trial name
- x-МАР (NCT06949982)
- Testing
- experimental group x-MAP, Regorafenib (BAY 73-4506)
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Orlov, MD
Colorectal Cancer, Metastatic Colorectal Cancer
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
FC-8 is a Phase II, multi-center randomized study of a continuation regimen of 5-FU/LV with ziv-aflibercept or 5-FU/LV alone (control arm) following the induction regimen of mFOLFOX6 and ziv-aflibercept as first-line therapy for…
- Trial name
- NCT01889680
- Testing
- 5-FU, LV, ziv-aflibercept
- Sponsor
- NSABP Foundation Inc
Colorectal Carcinoma, Neoplasms, Colorectal
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
The investigators hypothesize that glutamine significantly reduces the incidence and severity of peripheral neuropathy in patients receiving oxaliplatin for metastatic colorectal cancer, decreases the need for dose reduction of…
- Conditions
- Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer, Colorectal Tumors
- Trial name
- NCT01157039
- Testing
- Glutamine
- Sponsor
- AHS Cancer Control Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.